skip to main content
10.1145/3608164.3608171acmotherconferencesArticle/Chapter ViewAbstractPublication PagesicbbtConference Proceedingsconference-collections
research-article

Inference of Synthetically Lethal Pairs of Genes Involved in Metastatic Processes via Non-Negative Matrix Tri-Factorization

Published: 07 November 2023 Publication History

Abstract

Metastases formation dramatically represents the most widespread cause of cancer-related deaths; to date, however, few agents are specifically designed to contrast this phenomenon. In the last years, the concept of synthetic lethality (SL) for the design of new therapies has been effectively analysed and exploited. For the proper employment of this concept, a reliable computational identification of genetic SL pairs is required; massive use of laboratory-based methods is unfeasible due to the huge number of possible gene combinations. Non-Negative Matrix Tri-Factorization is emerging as an effective prediction method for inferring gene-to-gene relationships, and we hereby apply it to the inference of unknown SL gene pairs. The method is based on the decomposition of an association matrices in three non-negative matrices and their reconstruction. Here, the method is applied to data from SynLethDB, the most complete SL dataset, projected over metastatic genes. We show, by means of classical indicators, that he method is effective in inferring unseen pairs; we also demonstrate that the evaluation metric raises when we include in the prediction also other datasets describing gene features, that we properly include in the computation by means of additional matrices on the side of the main SL one. In this enhanced setting, we show that the method infers novel SL pairs, some of which independently supported by the literature.

References

[1]
Andrew J Aguirre and William C Hahn. 2018. Synthetic lethal vulnerabilities in KRAS-mutant cancers. Cold Spring Harbor perspectives in medicine 8, 8 (2018), a031518.
[2]
Robin L Anderson, Theo Balasas, Juliana Callaghan, R Charles Coombes, Jeff Evans, Jacqueline A Hall, Sally Kinrade, David Jones, Paul S Jones, Rob Jones, 2019. A framework for the development of effective anti-metastatic agents. Nature Reviews Clinical Oncology 16, 3 (2019), 185–204.
[3]
Gaia Ceddia, Pietro Pinoli, Stefano Ceri, and Marco Masseroli. 2020. Matrix factorization-based technique for drug repurposing predictions. IEEE journal of biomedical and health informatics 24, 11 (2020), 3162–3172.
[4]
The Gene Ontology Consortium. 2021. The Gene Ontology resource: enriching a GOld mine. Nucleic acids research 49, D1 (2021), D325–D334.
[5]
Andrej Čopar, Blaž Zupan, and Marinka Zitnik. 2019. Fast optimization of non-negative matrix tri-factorization. PloS one 14, 6 (2019), e0217994.
[6]
Marco Cordani, Elisa Oppici, Ilaria Dando, Elena Butturini, Elisa Dalla Pozza, Mercedes Nadal-Serrano, Jordi Oliver, Pilar Roca, Sofia Mariotto, Barbara Cellini, 2016. Mutant p53 proteins counteract autophagic mechanism sensitizing cancer cells to mTOR inhibition. Molecular oncology 10, 7 (2016), 1008–1029.
[7]
Chris Ding, Tao Li, Wei Peng, and Haesun Park. 2006. Orthogonal nonnegative matrix t-factorizations for clustering. In Proceedings of the 12th ACM SIGKDD international conference on Knowledge discovery and data mining. 126–135.
[8]
Th Dobzhansky. 1946. Genetics of natural populations. XIII. Recombination and variability in populations of Drosophila pseudoobscura. Genetics 31, 3 (1946), 269.
[9]
Yari Fontebasso and Steven M Dubinett. 2015. Drug development for metastasis prevention. Critical Reviews™ in Oncogenesis 20, 5-6 (2015).
[10]
Aneta Gandalovičová, Daniel Rosel, Michael Fernandes, Pavel Veselỳ, Petr Heneberg, Vladimír Čermák, Luboš Petruželka, Sunil Kumar, Victoria Sanz-Moreno, and Jan Brábek. 2017. Migrastatics—anti-metastatic and anti-invasion drugs: promises and challenges. Trends in cancer 3, 6 (2017), 391–406.
[11]
Marc Gillespie, Bijay Jassal, Ralf Stephan, Marija Milacic, Karen Rothfels, Andrea Senff-Ribeiro, Johannes Griss, Cristoffer Sevilla, Lisa Matthews, Chuqiao Gong, 2022. The reactome pathway knowledgebase 2022. Nucleic acids research 50, D1 (2022), D687–D692.
[12]
Douglas Hanahan and Robert A Weinberg. 2011. Hallmarks of cancer: the next generation. cell 144, 5 (2011), 646–674.
[13]
Jiahao Hu, Jiasheng Cao, Win Topatana, Sarun Juengpanich, Shijie Li, Bin Zhang, Jiliang Shen, Liuxin Cai, Xiujun Cai, and Mingyu Chen. 2021. Targeting mutant p53 for cancer therapy: Direct and indirect strategies. Journal of hematology & oncology 14 (2021), 1–19.
[14]
Alan Huang, Levi A Garraway, Alan Ashworth, and Barbara Weber. 2020. Synthetic lethality as an engine for cancer drug target discovery. Nature reviews Drug discovery 19, 1 (2020), 23–38.
[15]
Jiang Huang, Min Wu, Fan Lu, Le Ou-Yang, and Zexuan Zhu. 2019. Predicting synthetic lethal interactions in human cancers using graph regularized self-representative matrix factorization. BMC bioinformatics 20, 19 (2019), 1–8.
[16]
Livnat Jerby-Arnon, Nadja Pfetzer, Yedael Y Waldman, Lynn McGarry, Daniel James, Emma Shanks, Brinton Seashore-Ludlow, Adam Weinstock, Tamar Geiger, Paul A Clemons, 2014. Predicting cancer-specific vulnerability via data-driven detection of synthetic lethality. Cell 158, 5 (2014), 1199–1209.
[17]
Minoru Kanehisa and Susumu Goto. 2000. KEGG: kyoto encyclopedia of genes and genomes. Nucleic acids research 28, 1 (2000), 27–30.
[18]
Sebastian Köhler, Michael Gargano, Nicolas Matentzoglu, Leigh C Carmody, David Lewis-Smith, Nicole A Vasilevsky, Daniel Danis, Ganna Balagura, Gareth Baynam, Amy M Brower, 2021. The human phenotype ontology in 2021. Nucleic acids research 49, D1 (2021), D1207–D1217.
[19]
Ho-June Lee, Guanglei Zhuang, Yi Cao, Pan Du, Hyo-Jin Kim, and Jeff Settleman. 2014. Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells. Cancer cell 26, 2 (2014), 207–221.
[20]
Joo Sang Lee, Avinash Das, Livnat Jerby-Arnon, Rand Arafeh, Noam Auslander, Matthew Davidson, Lynn McGarry, Daniel James, Arnaud Amzallag, Seung Gu Park, 2018. Harnessing synthetic lethality to predict the response to cancer treatment. Nature communications 9, 1 (2018), 1–12.
[21]
Shijie Li, Win Topatana, Sarun Juengpanich, Jiasheng Cao, Jiahao Hu, Bin Zhang, Diana Ma, Xiujun Cai, and Mingyu Chen. 2020. Development of synthetic lethality in cancer: molecular and cellular classification. Signal Transduction and Targeted Therapy 5, 1 (2020), 241.
[22]
Herty Liany, Anand Jeyasekharan, and Vaibhav Rajan. 2020. Predicting synthetic lethal interactions using heterogeneous data sources. Bioinformatics 36, 7 (2020), 2209–2216.
[23]
Arthur Liberzon, Aravind Subramanian, Reid Pinchback, Helga Thorvaldsdóttir, Pablo Tamayo, and Jill P Mesirov. 2011. Molecular signatures database (MSigDB) 3.0. Bioinformatics 27, 12 (2011), 1739–1740.
[24]
Weijun Liu and Xiaowei Wang. 2019. Prediction of functional microRNA targets by integrative modeling of microRNA binding and target expression data. Genome biology 20 (2019), 1–10.
[25]
Yong Liu, Min Wu, Chenghao Liu, Xiao-Li Li, and Jie Zheng. 2019. SL 2 MF: Predicting synthetic lethality in human cancers via logistic matrix factorization. IEEE/ACM transactions on computational biology and bioinformatics 17, 3 (2019), 748–757.
[26]
Christopher J Lord and Alan Ashworth. 2017. PARP inhibitors: Synthetic lethality in the clinic. Science 355, 6330 (2017), 1152–1158.
[27]
Marvin Martens, Ammar Ammar, Anders Riutta, Andra Waagmeester, Denise N Slenter, Kristina Hanspers, Ryan A. Miller, Daniela Digles, Elisson N Lopes, Friederike Ehrhart, 2021. WikiPathways: connecting communities. Nucleic acids research 49, D1 (2021), D613–D621.
[28]
Kevin J Metcalf, Alaa Alazzeh, Zena Werb, Valerie M Weaver, 2021. Leveraging microenvironmental synthetic lethalities to treat cancer. The Journal of Clinical Investigation 131, 6 (2021).
[29]
Nigel J O’Neil, Melanie L Bailey, and Philip Hieter. 2017. Synthetic lethality and cancer. Nature Reviews Genetics 18, 10 (2017), 613–623.
[30]
Rose Oughtred, Jennifer Rust, Christie Chang, Bobby-Joe Breitkreutz, Chris Stark, Andrew Willems, Lorrie Boucher, Genie Leung, Nadine Kolas, Frederick Zhang, 2021. The BioGRID database: A comprehensive biomedical resource of curated protein, genetic, and chemical interactions. Protein Science 30, 1 (2021), 187–200.
[31]
Parasvi S Patel, Arash Algouneh, and Razq Hakem. 2021. Exploiting synthetic lethality to target BRCA1/2-deficient tumors: where we stand. Oncogene 40, 17 (2021), 3001–3014.
[32]
Janet Piñero, Juan Manuel Ramírez-Anguita, Josep Saüch-Pitarch, Francesco Ronzano, Emilio Centeno, Ferran Sanz, and Laura I Furlong. 2020. The DisGeNET knowledge platform for disease genomics: 2019 update. Nucleic acids research 48, D1 (2020), D845–D855.
[33]
Pietro Pinoli, Gaia Ceddia, Stefano Ceri, and Marco Masseroli. 2021. Predicting drug synergism by means of non-negative matrix tri-factorization. IEEE/ACM Transactions on Computational Biology and Bioinformatics (2021).
[34]
Daniel Rosel, Michael Fernandes, Victoria Sanz-Moreno, and Jan Brábek. 2019. Migrastatics: redirecting R&D in solid cancer towards metastasis?Trends in Cancer 5, 12 (2019), 755–756.
[35]
Andrew D Rouillard, Gregory W Gundersen, Nicolas F Fernandez, Zichen Wang, Caroline D Monteiro, Michael G McDermott, and Avi Ma’ayan. 2016. The harmonizome: a collection of processed datasets gathered to serve and mine knowledge about genes and proteins. Database 2016 (2016).
[36]
Carl F Schaefer, Kira Anthony, Shiva Krupa, Jeffrey Buchoff, Matthew Day, Timo Hannay, and Kenneth H Buetow. 2009. PID: the pathway interaction database. Nucleic acids research 37, suppl_1 (2009), D674–D679.
[37]
Carolina Testa, Sara Pidò, and Pietro Pinoli. 2022. A Non-Negative Matrix Tri-Factorization Based Method for Predicting Antitumor Drug Sensitivity. In International Meeting on Computational Intelligence Methods for Bioinformatics and Biostatistics. Springer, 94–104.
[38]
Win Topatana, Sarun Juengpanich, Shijie Li, Jiasheng Cao, Jiahao Hu, Jiyoung Lee, Kenneth Suliyanto, Diana Ma, Bin Zhang, Mingyu Chen, 2020. Advances in synthetic lethality for cancer therapy: Cellular mechanism and clinical translation. Journal of Hematology & Oncology 13, 1 (2020), 1–22.
[39]
Jie Wang, Min Wu, Xuhui Huang, Li Wang, Sophia Zhang, Hui Liu, and Jie Zheng. 2022. SynLethDB 2.0: A web-based knowledge graph database on synthetic lethality for novel anticancer drug discovery. Database 2022 (2022).
[40]
Jing Wang, Qinglong Zhang, Junshan Han, Yanpeng Zhao, Caiyun Zhao, Bowei Yan, Chong Dai, Lianlian Wu, Yuqi Wen, Yixin Zhang, 2022. Computational methods, databases and tools for synthetic lethality prediction. Briefings in Bioinformatics 23, 3 (2022), bbac106.
[41]
Xiaosheng Wang and Richard Simon. 2013. Identification of potential synthetic lethal genes to p53 using a computational biology approach. BMC medical genomics 6, 1 (2013), 1–10.
[42]
Hao Ye, Xiuhua Zhang, Yunqin Chen, Qi Liu, and Jia Wei. 2016. Ranking novel cancer driving synthetic lethal gene pairs using TCGA data. Oncotarget 7, 34 (2016), 55352.
[43]
Zehua Zhu, Amir R Aref, Travis J Cohoon, Thanh U Barbie, Yu Imamura, Shenghong Yang, Susan E Moody, Rhine R Shen, Anna C Schinzel, Tran C Thai, 2014. Inhibition of KRAS-Driven Tumorigenicity by Interruption of an Autocrine Cytokine CircuitTargeting Oncogenic KRAS via Cytokine Suppression. Cancer discovery 4, 4 (2014), 452–465.

Cited By

View all
  • (2024)The molecular basis of the anticancer effect of statinsScientific Reports10.1038/s41598-024-71240-614:1Online publication date: 31-Aug-2024

Recommendations

Comments

Information & Contributors

Information

Published In

cover image ACM Other conferences
ICBBT '23: Proceedings of the 2023 15th International Conference on Bioinformatics and Biomedical Technology
May 2023
313 pages
ISBN:9798400700385
DOI:10.1145/3608164
This work is licensed under a Creative Commons Attribution International 4.0 License.

Publisher

Association for Computing Machinery

New York, NY, United States

Publication History

Published: 07 November 2023

Check for updates

Author Tags

  1. Anti-metastatic
  2. Cancer
  3. NMTF
  4. Synthetic Lethality

Qualifiers

  • Research-article
  • Research
  • Refereed limited

Funding Sources

Conference

ICBBT 2023

Contributors

Other Metrics

Bibliometrics & Citations

Bibliometrics

Article Metrics

  • Downloads (Last 12 months)12
  • Downloads (Last 6 weeks)1
Reflects downloads up to 02 Mar 2025

Other Metrics

Citations

Cited By

View all
  • (2024)The molecular basis of the anticancer effect of statinsScientific Reports10.1038/s41598-024-71240-614:1Online publication date: 31-Aug-2024

View Options

Login options

View options

PDF

View or Download as a PDF file.

PDF

eReader

View online with eReader.

eReader

HTML Format

View this article in HTML Format.

HTML Format

Figures

Tables

Media

Share

Share

Share this Publication link

Share on social media